Comparative efficacy and safety and efficacy of systemic 13-cis retinoic acid 20mg/day vs. 40mg/day in acne vulgaris

Journal of Pakistan Association of Dermatologists

Volumn 15, Issue 3, 2005, Pages 238-241

  Kapadia, Naseema Fakhruddin ^a   Khalid, Gulnaz ^a   Burhany, Tasneem ^b   Nakhoda, Tasneem ^c  

^a ABBASI SHAHEED HOSPITAL   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c Taj Medical Complex   (Pakistan)

Author keywords

13 cis retinoic acid; Acne vulgaris

Indexed keywords

DIANE; EMOLLIENT AGENT; ISOTRETINOIN;

ACNE VULGARIS; ARTICLE; CHEILITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; MENSTRUATION; MENTAL INSTABILITY; MULTICENTER STUDY; OUTPATIENT; PRESCRIPTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCAR FORMATION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 29244477541     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wilson BB. Acne vulgaris. Prim Care 1989; 16: 695-712.
2. Wessels F, Anderson AN, Kropman K. The cost effectiveness of isotretinoin in the treatment of acne part 3 a cost minimization pharmaco economic model. S Afr Med J 1999; 7: 791-4.
3. Farreli LN, Strauss JS, Strainer AM. The Treatment of severe cystic acne with 13-cis retinoic acids. J Am Acad Dermatol 1980; 3: 602-11.
4. Kapadia N, Khalid G, Burhany T. 13-cis retinoic acid (Ro accutane) a miracle drug in nodulocystic acne. Ann Abbassi Shaheed Hospital, Karachi. Med Dent Coll 2003; 8: 432-4.
5. Strauss JS, Peck GL, Oslon TG et al. Sebum composition during oral 13-cis retinoic acid administration. J Invest Dermatol 1978; 70: 228-31.
6. Strauss JS, Strainer AM, Farreli LN, Downing DT. The effects of marked inhibition of sebum production with 13-cis retinoic acid on skin surface lipid composition. J Invest Dermatol 1980; 74: 66-7.
7. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhea and acne. Dermatology 1998; 196: 140-7.
8. Leyden JJ, Mc Cindey KJ, Foflea AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986; 86: 390-3.
9. Doshi A, Zaheer A, Stiller MJ. A Comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997; 36: 416-8.
10. Katz RA, Jorgensen H, Nigra TP. Elevation of serum triglycerides from oral 13-cis retinoic acid in the disorder of keratinization. Arch Dermatol 1980; 3: 602-11.
11. Goldsmith LA, Bolognia JL, Callen JP et al. American Academy of Dermatology Concensus Conference on the safe and optimal use of isotretinoin: Summary and recommendation. J Am Acad Dermatol 2004; 98: 900-6.
12. Christina Y, Chia MD, Whitney Lane et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne. Arch Dermatol 2005; 141: 557-60.